Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised PR Event in connection with the acquisition of the golf tournament Nordea Masters
Mandate

Vinge has advised PR Event in connection with the acquisition of the golf tournament Nordea Masters

September 27, 2013

Vinge has acted for PR Event i Båstad AB in connection with the acquisition of the golf tournament Nordea Masters by way of an asset transfer from Scandinavian Masters AB. PR Event is part of the Lagardère Unlimited Group, active within e.g. events production and management, marketing rights and  the talent representation business. Nordea Masters forms part of the European Tour and is with its 50 000 visitors per year Sweden’s largest recurring sports event. Closing of the transaction took place on 24 September 2013.

Partner Michael Wigge and associates Peter Sundgren and Sofie Bjärtun (M&A) acted for PR Event in connection with the transaction together with, among others, specialists Christian Hybbinette (Commercial Agreements) and Fredrik Gustafsson (Employment).    

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025